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Abstract
Purpose The current study assessed the eYcacy and safety
of biweekly oxaliplatin combining oral tegafur–uracil/
leucovorin in treating chemonaive patients with advanced
gastric cancer.
Methods Eligible patients were 18–75 years old, had
stage IV disease or post-surgery recurrence, no prior palli-
ative chemotherapy, and an ECOG performance status of
0–2. Patients in the current study received 2-h i.v. infu-
sion of oxaliplatin at a dose of 100 mg/m2 after diluting in
500 mL 5% dextrose/water (dexan premedication), and 5-HT3
antagonist biweekly. Oral tegafur–uracil and leucovorin
was given at a dose of 300 mg/m2/day and 60 mg/day
three times daily from day 1 to 21, respectively, followed
by a 1-week rest. Response assessment was based on the
RECIST criteria and was performed every two courses.
Toxicity was assessed according to NCI common toxicity
criteria version 2.
Results From October 2003 to April 2006, 57 patients
were evaluated (55 eligible) with a median age of 61 years
(range 31–75). According to the assessment of response in
48 evaluable patients, partial response rate was 24/48
(50.0%) (95% CI: 35.23–64.73%) and stable disease was
observed in 11 patients (22.92%), and diseased progressed
in 13 patients (27.08%). Mean number of oxaliplatin cycles
was 3 (0.5–6.5). Median time to progression was 177 days.
Median overall survival was 318 days. Major-grade (III/IV)
toxicities were diarrhea 25.5%, vomiting 16.5%, anemia
10.9%, numbness 12.7%, thrombocytopenia 7.3%, neutro-
penia 3.6% and leucopenia 1.8%.
Conclusions Biweekly, oxaliplatin combining oral tega-
fur–uracil/leucovorin in treating patients with advanced
gastric cancer showed acceptable activity and manageable
toxicity.
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Gastric adenocarcinoma is a common cancer and common
cause of cancer deaths worldwide [1]. Most patients receive
curative surgical resection; however, many patients even-
tually relapse with local-regional recurrence or distant
metastases [2]. Approximately 20–30% of patients have
inoperable disease at diagnosis. Thus, the majority of
patients require palliative treatment at certain time-points.
Randomized trials have demonstrated that 5-Xuorouracil-
based (5-FU) or cisplatin-based (CDDP) chemotherapeutic
regimens may improve survival and quality of life in
patients with advanced gastric cancer compared with best
supportive care [3, 4]. Although there are no standard com-
bination regimens for advanced gastric cancer, 5-FU-based
and CPPD-based regimens are mostly used in clinical prac-
tice [4, 5].
Tegafur–uracil (uracil combined with tegafur in a 4:1
ratio) is a second-generation, oral 5-FU pro-drug. Uracil
prevents the degradation of 5-FU by inhibiting dehydropyr-
imidine dihydrogenase (DPD), and this leads to increased
concentrations of 5-FU in plasma and tumor tissue [6].
Tegafur–uracil, which is widely used in Asia, has been
approved for use in the treatment of metastatic colorectal,
gastric and breast cancer in our country, Taiwan. Prolonged
use of tegafur–uracil results in a similar or higher maxi-
mum concentration (Cmax) and area under the curve (AUC)
compared to that achieved by giving continuous infusion of
5-FU; however, pharmacokinetic patterns diVer [7, 8].
Phase II data suggested that tegafur–uracil and 5-FU had
similar activity against gastric cancer [9]. Patients’ toler-
ance to tegafur–uracil on a schedule of 28 days on/7 days
oV has been excellent. Common toxicities of tegafur–uracil
include anorexia, nausea and vomiting; diarrhea and hema-
tologic toxicity is rare. We hypothesized that it was worth-
while to study tegafur–uracil combining with other active
and novel chemotherapeutic agents to increase the response
rate and improve the survival of patients with advanced
gastric cancer.
Oxaliplatin (OXA), a new cytotoxic agent from the
diaminocyclohexane platinum family, has a mechanism of
action similar to that of other platinum derivatives, but its
spectrum of antitumor activity against tumor models diVers
from those of CDDP and carboplatin [10]. Experiments
have shown activity against CDDP-resistant colon carci-
noma cell lines and the synergistic activity of combined
OXA and 5-FU [10]. OXA’s clinical toxicity is distinct
from that of other platinum drugs in terms of the absence of
renal toxicity and minimal incidence of hematotoxicity; it
causes both reversible acute, cold-related dysesthesia and
dose-limiting cumulative peripheral sensory neuropathy
[11]. Its activity as a single agent in either chemonaive or
5-FU pretreated patients with metastatic colorectal cancer has
been demonstrated in phase II trials; response rates ranged
from 10 to 24% [12, 13]. Phase III study has conWrmed the
role of OXA combining with 5-FU/LV as standard care,
Wrst-line therapy for treating metastatic colorectal cancer
[14]. In a pilot study, patients with advanced scirrhous-type
gastric cancer who were given preoperative OXA showed a
clinical response with signiWcant platinum concentration
observed in tissue examined postoperatively [15]. The com-
bination of OXA, oral tegafur–uracil and LV has shown
synergistic antitumor activity against human colorectal
HT29 cell xenografts in athymic nude mice [16]. To date,
few data have been collected from phase I and II clinical
studies investigating the use of OXA combining oral tega-
fur–uracil and LV in patients with gastric cancer. The
advantage of such combination is that OXA does not
require hydration, and tegafur–uracil/LV can be given
orally in an outpatient setting. In a previous, dose-escala-
tion study, we established the recommended doses of OXA
and tegafur–uracil/LV in patients with advanced gastric
cancer [17]. In the current phase II study, primary end point
was the assessment of response rate. Secondary endpoints
were the assessment of time to progression, median sur-
vival, and drug-related toxicity. Herein, we reported the
Wnal results of this phase II study.
Patients and methods
Eligibility criteria
Eligibility criteria were as follows. Patients had to have a
histological or cytological diagnosis of gastric adenocarci-
noma with metastatic disease. Patients had to be ¸18 and
·75 years of age and have an ECOG performance status
score ·2. Patients had to have recovered from recent sur-
gery (procedure at least 2 weeks prior to enrollment) or
radiotherapy (completed at least 4 weeks prior to enroll-
ment) and have not had any palliative chemotherapy.
Patients with previous adjuvant and/or neoadjuvant chemo-
therapy were eligible if they had not been treated for over
6 months between the end of adjuvant chemotherapy and
the Wrst relapse. Patients had to have at least one measur-
able lesion at enrollment. Measurable lesions were deWned
as lesions that could be measured in at least one dimension
as ¸20 mm with conventional technique or ¸10 mm with
spiral computed tomography (CT). Previously irradiated
lesions were not considered measurable target lesions.
Patients were allowed to complete their initial work-up
within 2 weeks prior to receiving the Wrst cycle of chemo-
therapy in this trial.
Patients had to show baseline eligibility in laboratory tests
as follows: neutrophils ¸ 1,500/L, platelets ¸ 100,000/L,
serum creatinine · 1.5 £ upper limit of normal (ULN),123
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ULN (·5.0 £ ULN if hepatic metastasis present). Finally,
patients had to complete an informed consent form before
entering the study. This study was approved prior to imple-
mentation by the ScientiWc and Research Ethics Committees
of the participating institutions.
Exclusion criteria
Patients with the following conditions were excluded: life
expectancy less than 3 months, had central nervous system
metastasis, had bone metastasis only, pregnancy or breast-
feeding, clinically detectable peripheral neuropathy more
than grade 2 due to any causes, concomitant illness that
might be aggravated by chemotherapy, active cardiac disease
within 6 months preceding entry into the study (e.g., angina
or myocardial disease), history of other malignancy except
for curatively treated nonmelanoma skin cancer or cervical
carcinoma in situ, mental status unWt for clinical trials,
hypersensitive to any components of this chemotherapeutic
regimen, or intestinal obstruction, malabsorption or any
other condition that precluded taking oral study medication.
Treatment schedule
Oxaliplatin (OXALIP®, TTY Biopharm Co. Ltd, Taipei,
Taiwan) 100 mg/m2 was administered on days 1 and 15 as a
2-h infusion. Tegafur–uracil (UFUR® TTY Biopharm Co.
Ltd, Taipei, Taiwan)/LV was orally administered from
day 1 to day 21 followed by a 7-day break. The dose of
tegafur–uracil was 300 mg/m2/day (based on tegafur dose)
given orally in three divided doses every 8 h (approxi-
mately 7 am, 3 pm and 11 pm). If the capsule dose could
not be divided equally, the highest dose was administered
in the morning and the lowest dose administered in the
evening. LV was supplied as 15-mg tablets and was admin-
istered orally at a dose of 60 mg/day. LV was given to the
patients concurrently with tegafur–uracil; the Wrst LV dose
(7 am) was 30 mg followed by two subsequent doses of
15 mg given at 3 pm and 11 pm, respectively. Patients were
instructed to take 120–240 cc water with medication and
not to consume any food for 1 h before and after the inges-
tion of medication. The administration of tegafur–uracil/LV
was to be continued if the discontinuation of OXA was
required with the absence of disease progression. This regi-
men was repeated every 28 days as one treatment course.
Treatment was continued until objective evidence of dis-
ease progression was obtained, protocol noncompliance
was established or an individual patient wished to withdraw
from the study at his/her own request or if an investigator
felt that patient withdrawal was in the patient’s best interest
(for example, if surgery became acceptable).
Study evaluation
Tumor response was evaluated after every two courses
of chemotherapy according to the Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines [18].
Toxicities were recorded based on the National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version 2,
1998).
Statistical considerations
The primary endpoint was response rate. Secondary end-
points were time to progression, overall survival time and
drug-related toxicity. Time to progression was deWned as
the period from the Wrst day of drug treatment to the date
when progressive disease or relapse was clearly docu-
mented. Overall survival represented the number of days
until death from any cause. Safety variables included tox-
icity grading, adverse events and laboratory values. Based
on previous studied reports, a response rate of 30–60%
with an expected mean of approximately 50% was
assumed for the study regimen. Simon’s two-stage opti-
mal design was adapted to calculate the sample size for
type-I error of 0.05 and power of 80%. Based on the null-
hypothesized proportion of 30% and the research-hypoth-
esized proportion of 50%, Simon’s two-stage optimal
design determined that evaluable patients for stages I and
II were as follows: of the Wrst 15 patients enrolled, >5 (or
¸6) patients were required to show treatment response to
go to the second stage; otherwise, the trial would be termi-
nated. If the response outcome passed the Wrst stage, addi-
tional 31 patients would be recruited and >18 (or ¸19)
patients were required to show a response to conclude that
the study regimen was eVective. The sample size was




A total of 57 patients were screened according to study cri-
teria from October 2003 to April 2006 at six sites. Two
patients were not eligible for this study. Of the 55 eligible
patients, there were 20 women and 35 men (median age
61 years; range 31–75). Patient characteristics were as
shown in Table 1. Mean number of cycles of OXA admin-
istered was 3.82 (0.5–7.0). Mean cumulative dose of OXA
was 1,070.67 mg (150.0–2,312.0). Mean drug compliances
for tegafur–uracil and LV were 96.89% (29.0–100.0) and
97.05% (35.0–100.0), respectively.123
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By the end of June 2007, all participants had Wnished
receiving study treatment. The median follow-up duration
was 343 days (range 16–1,239). Seven patients were not
evaluated for response: one died during the Wrst month of
treatment secondary to pneumonia and gastrointestinal
bleeding; four patients could not tolerate therapy; one
patient had poor compliance; and one patient was removed
from the study at an investigator’s discretion. The remain-
ing 48 patients were evaluated for response: 24 patients
had partial response (50.0%, 95% CI: 35.23–64.73%), 11
patients had stable disease (22.92%) and 13 patients had
progression of disease (27.08%). The median time to pro-
gression and overall median survival time for all 55 patients
were 177 days (95% CI: 148–224 days) and 331 days (95%
CI: 253–415 days), respectively. The estimated 1-, 2- and
3-year survival rates were 41, 13 and 8%, respectively. The
most common causes for discontinuation from study treat-
ment in 48 evaluated patients were disease progression (26
patients, 54%) and adverse events (22 patients, 45.8%). The
most common adverse event that led to discontinuation of
participation in the study was numbness (14 patients, 29%).
Toxicity
Toxicity was assessed in all 55 patients (Table 2). The most
common hematological toxicity was thrombocytopenia,
and the most common nonhematological toxicity was diar-
rhea. The most common grade III/IV toxicity was diarrhea
(14/55, 25.4%), followed by vomiting (9/55, 16.4%),
numbness (12/55, 12.7%), anemia (6/55, 10.9%), nausea
(5/55, 9.1%), thrombocytopenia (4/55, 7.3%) and neutrope-
nia (3/55, 5.5%).
Discussion
Since 2002, biweekly or weekly, OXA with 5FU-LV given
as 24-h or 48-h infusion by pump has been studied in sev-
eral phase II trials involving patients with advanced gastric
cancer [19–22]. Reported response rates have ranged from
43 to 56%, with time to progression ranging from 5.2 to
6.5 months and overall median survival ranging from 8.6 to
11.4 months, respectively. Major toxicities were myelotox-
icity and neuropathy. In comparison with previous regi-
mens, OXA and 5-FU/LV combination showed better
eYcacy and tolerance. Therefore, authors encouraged the
Table 1 Patient characteristics (n = 55)
Characteristic No. of patients
Gender: female/male 20/35

















Table 2 Maximal adverse 
events among patients 
(NCI-CTC, version 2) 
(n = 55)
Grade I Grade II Grade III Grade IV
Leukopenia 12 (21.8%) 9 (16.4%) 1 (1.8%) 0
Neutropenia 11 (20.0%) 13 (23.6%) 3 (5.5%) 0
Anemia 8 (14.5%) 16 (29.1%) 5 (9.1%) 1 (1.8%)
Thrombocytopenia 22 (40.0%) 13 (23.6%) 3 (5.5%) 1 (1.8%)
Infection 1 (1.8%) 0 7 (12.7%) 2 (3.6%)
Nausea 10 (18.2%) 7 (12.7%) 4 (7.3%) 1 (1.8%)
Vomiting 16 (29.1%) 3 (5.5%) 5 (9.1%) 4 (7.3%)
Stomatitis 3 (5.5%) 3 (5.5%) 0 0
Diarrhea 11 (20.0%) 5 (9.1%) 11 (20.0%) 3 (5.5%)
Neuropathy 12 (21.8%) 14 (25.5%) 6 (10.9%) 1 (1.8%)
Asthenia 12 (21.8%) 9 (16.4%) 2 (3.6%) 0
Liver 19 (34.5%) 8 (14.5%) 4 (7.3%) 0
Renal 1 (1.8%) 2 (3.6%) 0 0123
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men.
Oral tegafur–uracil/LV is commonly used for gastric
cancer in Asia and appears to have similar eYcacy with
bolus 5-FU/LV in patients with advanced colorectal cancer.
OXA combining with oral tegafur–uracil/LV without using
pumps appears to be an attractive alternative to infusion of
5-FU/LV. Such combination chemotherapy treatment used
in the current study produced a 50% response rate, time to
progression of 177 days and median survival of 331 days.
The major toxicity was diarrhea. Results of this phase II
study resemble those of the previous phase I dose-Wnding
study [17]. The major barrier for the patients to receive
complete doses of this regimen was the occurrence of diar-
rhea. The results were comparable with those of several
previous phase II studies using the combination OXA and
infusion 5-FU/LV [19–22]. EYcacy and median survival
were similar to the results shown in previous reports with
the exception of toxicity proWles. Grade III/IV myelotoxic-
ity in the current study was less than 10%. In contrast, the
regimen of OXA combining infusional 5-FU/LV induced a
much higher rate of myelotoxicity (more than 20%) and
less frequent rate of diarrhea (less than 10%). Jatoi et al.
reported that OXA and oral capcetabine for advanced
gastroesophageal cancer was associated with grade III/IV
diarrhea in 30% of patients [23]. Park et al. used the same
schedule as Jatoi et al.’s study for 20 patients with
advanced gastric cancer [24]. The response rate reported
in their study was 65%, with grade III/IV toxicities of diar-
rhea, neutropenia and vomiting (all in less than 5% of
patients). Obviously, the major limitation for clinical appli-
cation of OXA and oral tegafur–uracil/LV is diarrhea
instead of hand-foot syndrome. Our suggestions for pre-
venting severe diarrhea are as follows: Wrstly, reduce OXA
dose to 85 mg/m2 biweekly in future trials based on experi-
ence from our initial dose-escalation study [17]; secondly,
avoid the use of this combination in patients who present
with poor baseline gastrointestinal function; thirdly, replace
tegafur–uracil/LV with S-1 in future trials. S-1 is a novel
oral Xuroropyrimidine, which was reported to have a single
agent response rate of 44% in treating advanced gastric
cancer with a grade III/IV diarrhea rate of only 2% [25].
EYcacy and toxicity of OXA and oral tegafur–uracil/LV
have not yet been reported in the treatment of gastric can-
cer, but both chemotherapeutic agents have been studied
extensively in colorectal cancer in both advance and adju-
vant setting. The Oncopaz Cooperative Group used OXA
85 mg/m2 biweekly with oral tegafur–uracil 390 mg/m2/day
and oral LV in treating patients with advanced colon cancer
[26]. In the beginning of the study, the Wrst 16 patients
showed 56% incidence rate of grade III/IV diarrhea; after
the dose of tegafur–uracil was reduced to 300 mg/m2/day
for the next 66 patients, the incidence rate of grade III/IV
diarrhea was reduced dramatically to 21%. In another
study, which enrolled patients older than 70 years who had
advanced colorectal cancer, OXA was given at a dose of
65 mg/m2 on days 1 and 8 with oral tegafur–uracil 300 mg/
m2/day and LV 90 mg/day given for 14 days in a 3-week
schedule [27]. The authors concluded that this combination
regimen had acceptable activity and good tolerability with
maintenance of quality of life in this population of patients.
In these patients, major grade III/IV toxicities were diarrhea
(16.9%) and peripheral neuropathy (12.7%). In 2006,
Bennouna et al. reported results of the regimen of OXA
130 mg/m2 given on day 1 combining the administration of
oral tegafur–uracil 300 mg/m2/day and LV 90 mg/day from
day 1 to 14 in a 21-day cycle (TEGAFOX) used as Wrst-line
treatment for patients with metastatic colorectal cancer
[28]. Major grade III/IV toxicities caused by the abovemen-
tioned regimen were sensory neuropathy (15%), asthenia
(13%) and diarrhea (11%). From our studies and review of
the literature, OXA combining oral tegafur–uracil/LV
appears to be a promising alternative for patients who are
not suitable for or refuse to receive intravenous infusion of
5-FU.
Recently, several novel agents were evaluated for
advanced gastric cancer. The V325 study [29] demon-
strated that patients treated with doxcetaxel, CDDP and
5-FU (DCF) had better response and survival beneWts than
patients treated with CDDP and 5-FU (CF). DCF was sug-
gested for use as a reference treatment for advanced gastric
cancer. However, treatment with DCF resulted in a much
higher percentage of hematologic toxicity than seen in the
CF arm. This might be a limitation for use in conventional
clinical practice. Recently, the Wnal results from the REAL
2 study [30] showed that OXA and oral capcetabine could
replace CDDP and low-dose infusion 5-FU given by pump
for patients with esophagogastric junction cancer. To date,
no clinical data could demonstrate whether one oral Xuoro-
pyridime is better than the other.
The major toxicity of tegafur–uracil/LV is diarrhea, and
bone marrow toxicity is limited. The main limitations of
capcetabine are diarrhea and hand-foot syndrome. S-1
causes fewer diarrheas but has higher incidence of bone
marrow toxicity [31]. In the clinical practice, we can
choose or change the diVerent Xuoropyridimes depending
on physicians’ experiences, patient’s age and baseline
symptoms. In addition, possible side eVects that may hap-
pen during treatment should be closely monitored. The best
measure is to integrate various aspects of tumor biology
(i.e. thmidylate synthase and dihydropyrimidine dehydro-
genase activity), which may predict sensitivity to particular
drugs and allow individualization of therapy [31]. Further
research is needed to identify the most active and conve-
nient combination regimen with least toxic combinations
for patients with advanced gastric cancer.123
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lation between tumor response to Wrst-line chemotherapy
and prognosis in patients with advanced gastric cancer [32].
They demonstrated the following: Wrstly, response rate
might not be a valid surrogate for survival for the purpose
of testing a new treatment; secondly, time to progression of
roughly 5 months was considered a threshold point regard-
less of increasing response rate; thirdly, eVective second-
line chemotherapy may aVect the outcome of patients with
advanced gastric cancer. For regimens based on OXA
and 5-FU, times to progression were almost more than
5 months. In the future, OXA-based chemotherapy with
5-FU may be considered one of the reference treatment for
patients with advanced gastric cancer.
In conclusion, the combination of biweekly OXA and
tegafur–uracil/LV in patients with advanced gastric cancer
has acceptable activity and manageable toxicity. EYcacy
data shown in current phase II trial was similar to the
results reported in the previous studies using OXA and
infusion 5-FU/LV. The safety proWles diVered with a higher
incidence of diarrhea but with less severe hematologic tox-
icities. Further study is warranted involving oxaliplatin
combining diVerent oral Xuoropyrimidine drugs.
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